+1-206-701-6702
+44-020-8133-4027
+81-50-5539-1737
+91-848-285-0837
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
An infusion product is a medical device that delivers fluids into a patient's body in controlled amounts such as nutrients and medications. Infusion pumps are commonly used in clinical settings such as hospitals, nursing homes, and home care settings.
An infusion pump is typically operated by a trained user, who programs the rate and duration of fluid delivery via a built-in software interface. Infusion pumps have significant advantages over manual fluid administration including the ability to deliver fluids in very small volumes and at precisely programmed rates or automated intervals.
They can deliver nutrients as well as medications such as insulin or other hormones, antibiotics, chemotherapy drugs, and pain relievers.
U.S. IV Infusion Products Market - Impact of the Coronavirus (COVID-19) Pandemic
Coronavirus (COVID-19) outbreak was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared COVID-19 as pandemic on March 11, 2020. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 213 million cases and 4.48 million deaths due to coronavirus disease (COVID-19) were reported till August 25, 2021, across the globe.
Impact of COVID-19 on Demand and Supply of IV Infusion Products
The COVID-19 pandemic and lockdown in various countries across the globe have impacted the financial status of businesses across all sectors including private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry mainly due to strict lockdown in several regions. The COVID-19 pandemic has affected the economy of various regions across the globe in three main ways; 1) by directly affecting the production and demand; 2) by creating disruptions in distribution channels; and 3) through its financial impact on companies and financial markets. Many countries such as Thailand, Indonesia, and Singapore are facing problems with regards to transportation and distribution of healthcare products.
However, the coronavirus (COVID-19) pandemic is expected to drive growth of the U.S. IV infusion products market during the forecast period, owing to increasing demand for infusion pumps in COVID-19 patients. For instance, according to Flex Ltd., a multinational electronics contract manufacturer, Singapore, as COVID-19 patients began to fill hospital intensive care units (ICU), infusion pump demand quickly surged. A flood of orders was sent to suppliers, putting pressure on them to manufacture even more. Flex's Timisoara, Romania, facility had been producing infusion pumps for many years, however, in 2020, during the COVID-19 pandemic, the team had to manufacture five times as many infusion pumps, in order to cater to the rising demand.
The U.S. IV infusion products market is estimated to be valued at US$ 7,885.4 Mn in 2021, and is expected to exhibit a CAGR of 3.8% over the forecast period (2021-2028).
Figure 1: U.S. IV Infusion Products Market Share (%) Analysis, By Product Type, 2021
The increasing prevalence of chronic diseases is the major factor that is expected to drive growth of the U.S. IV infusion products market over the forecast period.
The increasing prevalence of chronic diseases is expected to drive growth of the U.S. IV infusion products market as the IV Infusion products are used for various purposes in chronic diseases such as blood transfusions, chemotherapy, and for administration of intravenous fluids and antibiotic. For instance, according to the article published by the National Health Council, U.S., in 2019, a chronic disease is defined as a disease, which lasts for three months or longer. According to the same source, around, 40 million of the U.S. population are suffering from one or the other chronic disease such as diabetes, heart disease, cancers, chronic lung diseases, stroke, Alzheimer's disease, chronic kidney disease, and others.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2020 | Market Size in 2021: | US$ 7,885.4 Mn |
| Historical Data for: | 2017 to 2020 | Forecast Period: | 2021 to 2028 |
| Forecast Period 2021 to 2028 CAGR: | 3.8% | 2028 Value Projection: | US$ 10,238.5 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
AngioDynamics Inc., Kimal, Terumo Corporation, Teleflex Inc., Becton Dickinson and Company, Cook Group, Nipro Corporation, ZOLL Medical Corporation, B. Braun Medical Inc., AdvaCare Pharma, PL Medical Co.LLC, Greiner Bio-One International GmbH, EMED Technologies Corporation, CODAN Companies, and Smiths Group plc. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Certifications from Regulatory Authorities
Increasing certifications from the regulatory authorities for the IV infusion products is expected to provide lucrative growth opportunities for players operating in the U.S. IV infusion products market. For instance, on July 22, 2021, Innovative Health Sciences, LLC, a medical device company focused on developing and commercializing home infusion therapy based in U.S., announced that it received CE Mark Certification for its product, Insignis Syringe Infusion System. Insignis syringe infusion system is the first combination of intravenous and subcutaneous non-electric infusion pump created for use with a selectable rate flow controller, IV controller, and the OneSett.
U.S. IV Infusion Products Market – Restraints
Complications associated with using IV route and IV infusion products is expected to hamper growth of the U.S. IV infusion products market. For instance, according to the article published in the International Journal of Pharmaceutical Studies and Research, 2017, there are many disadvantages associated with administration of drugs through IV route and use of IV products such as pain is felt at the site of injections, extravasation of some drugs can cause injury, necrosis, and sloughing of tissues and severe adverse effect especially when organs such as liver, heart, brain are involved in toxicity.
Figure 2: U.S. IV Infusion Products Market Value (US$ Mn) & Y-o-Y Growth (%), 2020 - 2028
U.S. IV Infusion Products Market – Competitive Landscape
Major players operating in the U.S. IV infusion products market include AngioDynamics Inc., Kimal, Terumo Corporation, Teleflex Inc., Becton Dickinson and Company, Cook Group, Nipro Corporation, ZOLL Medical Corporation, B. Braun Medical Inc., AdvaCare Pharma, PL Medical Co., LLC, Greiner Bio-One International GmbH, EMED Technologies Corporation, CODAN Companies, and Smiths Group plc.
The administration of drugs via a needle or catheter is known as infusion treatment. Infusion therapy refers to administration of a medicine intravenously or subcutaneously. A medical device that consists of a thin tube attached to a pump is known as an infusion catheter. A cavity, duct, or vessels in the body holds the thin tube. Infusion catheters are frequently implanted in chemotherapy patients to get reliable intravenous access.
Market Dynamics
Market players are focused on product launches or approvals, which is expected to drive growth of the U.S. IV infusion products market over the forecast period. For instance, on February 8, 2016, AngioDynamics Inc., a provider of medical devices, received approval from the Health Canada for its Celerity PICC Tip Confirmation System developed for the positioning of peripherally inserted central catheters (PICC) in adult patients. Celerity with navigation adds real-time catheter tracking to the prior version of the tip localization system, allowing doctors to view the location of the PICC tip at all times and improving the clinician experience.
U.S. IV infusion product market is estimated to witness significant growth, owing to various reimbursement scenarios for infusion products in the U.S. For instance, according to the Center for Medicare & Medicaid Services (CMS), the following products are available for reimbursement:
| Code | Product Description |
|
E0776 |
IV POLE |
|
E0779 |
Ambulatory infusion pump, mechanical, reusable for infusion of 8 hours or greater |
|
E0780 |
Ambulatory infusion pump, mechanical, reusable for infusion less than 8 hours |
|
E0781 |
Ambulatory infusion pump, single or multiple channels, electric or battery operated, with administrative equipment, worn by patient
|
|
E0784 |
External ambulatory infusion pump
|
Market players are involved in expanding their global presence by adopting strategies such as acquisitions and partnerships, and this is expected to drive growth of the U.S. IV infusion products market. For instance, on August 21, 2019, B. Braun Medical Inc. and Steward Health Care, a private, physician-led health care network in the U.S., entered into a seven year agreement to purchase IV solutions and Infusomat and Perfusor space pumps. As part of this long-term agreement, Steward Health Care will install over 5,000 Infusomat and Perfusor cordless space pumps in its 36 domestic hospitals and outpatient facilities.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
*Key pointers provided are also applicable to other companies covered in the scope of the report.
*Browse 20 market data tables and 54 figures on “IV Infusion Products Market” - Global Forecast to 2028.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
Contact Us
